Japan Tissue Engineering Co., Ltd. (TYO:7774)
594.00
-7.00 (-1.16%)
Jun 3, 2026, 3:30 PM JST
Japan Tissue Engineering Revenue
In the fiscal year ending March 31, 2026, Japan Tissue Engineering had annual revenue of 2.18B JPY, down -11.12%. Japan Tissue Engineering had revenue of 672.40M in the quarter ending March 31, 2026, a decrease of -10.18%.
Revenue
2.18B
Revenue Growth
-11.12%
P/S Ratio
11.18
Revenue / Employee
10.70M
Employees
204
Market Cap
24.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.18B | -273.00M | -11.12% |
| Mar 31, 2025 | 2.46B | -59.00M | -2.35% |
| Mar 31, 2024 | 2.51B | 482.00M | 23.72% |
| Mar 31, 2023 | 2.03B | -71.00M | -3.38% |
| Mar 31, 2022 | 2.10B | -154.00M | -6.82% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.81B |
| ReproCELL | 2.23B |
| Immuno-Biological Laboratories | 1.00B |
| AnGes | 908.00M |
| Stella Pharma | 323.00M |
| Cuorips | 212.00M |
| Nano Holdings | 174.00M |
| Healios K.K. | 74.00M |